You have 9 free searches left this month | for more free features.

Lymphoma, Non-Hodgkin

Showing 26 - 50 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Non Hodgkin Lymphoma Trial in Philadelphia (Pembrolizumab)

Recruiting
  • Non Hodgkin Lymphoma
  • Philadelphia, Pennsylvania
    Abamson Cancer Center of the University of Pennsylvania
Jan 9, 2023

Refractory or Relapsed B-cell Non-Hodgkin Lymphoma Trial in Shanghai (dualCAR-NK19/70 cell)

Recruiting
  • Refractory or Relapsed B-cell Non-Hodgkin Lymphoma
  • dualCAR-NK19/70 cell
  • Shanghai, Shanghai, China
    Shanghai Tongji Hospital, Tongji University School of Medicine
Apr 24, 2023

Advanced Solid Tumor, Refractory Non-Hodgkin Lymphoma Trial (HCB101)

Not yet recruiting
  • Advanced Solid Tumor
  • Refractory Non-Hodgkin Lymphoma
  • (no location specified)
May 28, 2023

(CHANT)Real World Study of Duvelisib in Treatment of

Not yet recruiting
  • Follicular Lymphoma
  • +5 more
  • (no location specified)
Jun 20, 2023

Lymphoma, Non-Hodgkin, Diffuse Large B Cell Lymphoma Trial in Tianjin (CD19-targeted Chimeric Antigen Receptor(CAR) T Cells)

Recruiting
  • Lymphoma, Non-Hodgkin
  • Diffuse Large B Cell Lymphoma
  • CD19-targeted Chimeric Antigen Receptor(CAR) T Cells
  • Tianjin, Tianjin, China
    Tianjin Cancer Hospital
Nov 19, 2023

Lymphoma, Non-Hodgkin, Myeloma Multiple Trial (Connected scale "Body Comp Pro" from Withings)

Not yet recruiting
  • Lymphoma, Non-Hodgkin
  • Myeloma Multiple
  • Connected scale "Body Comp Pro" from Withings
  • (no location specified)
Nov 9, 2023

CD20-positive B-cell Non-Hodgkin's Lymphoma Trial in Beijing (IMM0306)

Recruiting
  • CD20-positive B-cell Non-Hodgkin's Lymphoma
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Apr 6, 2023

Living Conditions After Non-Hodgkin's Lymphoma in France

Not yet recruiting
  • Non-hodgkin's Lymphoma
  • Data collection
  • Questionnaires
  • Dijon, France
    Chu Dijon Bourgogne
Oct 13, 2022

Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia Trial (BGB-21447)

Not yet recruiting
  • Relapsed Non-Hodgkin Lymphoma
  • +6 more
  • (no location specified)
Apr 12, 2023

DLBCL - Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma Trial (Bridging radiation therapy,

Not yet recruiting
  • DLBCL - Diffuse Large B Cell Lymphoma
  • +6 more
  • Bridging radiation therapy
  • +2 more
  • (no location specified)
Jan 4, 2023

Advanced or Metastatic Solid Tumors, Non-Hodgkin Lymphoma Trial in San Antonio (WTX-330)

Recruiting
  • Advanced or Metastatic Solid Tumors
  • Non-Hodgkin Lymphoma
  • San Antonio, Texas
    NEXT Oncology
Jan 6, 2023

Fractionated Rituximab to Avoid Lysis Syndrome in Aggressive

Active, not recruiting
  • Aggressive B-Cell Non-Hodgkin Lymphoma
  • fractionated first dose rituximab
  • Geneva, Switzerland
    University Hospital Geneva
Apr 21, 2023

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

Relapsed or Refractory Non-Hodgkin's Lymphoma Trial in China (AXT-1003)

Not yet recruiting
  • Relapsed or Refractory Non-Hodgkin's Lymphoma
  • Beijing, China
  • +3 more
Jul 20, 2023

Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory, Advanced Solid Tumor Trial (TR115)

Not yet recruiting
  • Non-Hodgkin's Lymphoma, Relapsed
  • +2 more
  • (no location specified)
Dec 6, 2022

Immunogenicity of COVID-19 Vaccinations in Autologous HSCT

Not yet recruiting
  • COVID-19
  • +2 more
    • Cologne, NRW, Germany
      University Hospital of Cologne
    Oct 27, 2022

    B-cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial (IKS03)

    Not yet recruiting
    • B-cell Non-Hodgkin Lymphoma
    • +4 more
    • (no location specified)
    Dec 7, 2022

    B-cell Non Hodgkin Lymphoma Trial in Hanzhou (CB dualCAR-NK19/70)

    Not yet recruiting
    • B-cell Non Hodgkin Lymphoma
    • CB dualCAR-NK19/70
    • Hanzhou, Zhejiang, China
      2nd Affiliated Hospital, School of Medicine, Zhejiang University
    Dec 25, 2022

    CD20-positive Non-Hodgkin Lymphoma Trial in Seoul (Rituximab + MG4101)

    Terminated
    • CD20-positive Non-Hodgkin Lymphoma
    • Rituximab + MG4101
    • Seoul, Korea, Republic of
      Seoul National University Hospital
    Oct 24, 2022

    Refractory Non-Hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma Trial in Duarte, Hackensack, Houston (SIRPant-M, External-beam

    Not yet recruiting
    • Refractory Non-Hodgkin Lymphoma
    • Relapsed Non-Hodgkin Lymphoma
    • SIRPant-M
    • External-beam radiotherapy (XRT)
    • Duarte, California
    • +2 more
    Jul 21, 2023

    Advanced Solid Tumors, Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Multiple Myeloma Trial in Gyeonggi-do,

    Recruiting
    • Advanced Solid Tumors
    • +2 more
    • GIC-102 (Allogeneic NK cells)
    • Gyeonggi-do, Korea, Republic of
    • +3 more
    May 18, 2023

    Non-Hodgkin Lymphoma, Large B-cell Lymphoma Trial in Palo Alto (Axicabtagene Ciloleucel)

    Not yet recruiting
    • Non-Hodgkin Lymphoma
    • Large B-cell Lymphoma
    • Axicabtagene Ciloleucel
    • Palo Alto, California
      Stanford University
    Mar 20, 2023

    B-cell Non-Hodgkin Lymphoma (B-NHL) Trial in Austin (UCART20x22, CLLS52)

    Recruiting
    • B-cell Non-Hodgkin Lymphoma (B-NHL)
    • UCART20x22
    • CLLS52
    • Austin, Texas
      Sarah Cannon - St. David South Austin Medical Center
    Dec 8, 2022

    Solid Tumor, Non-Hodgkin Lymphoma Trial in Guangzhou, Shanghai (ADG106)

    Active, not recruiting
    • Solid Tumor
    • Non-Hodgkin Lymphoma
    • Guangzhou, Guangdong, China
    • +1 more
    Oct 15, 2022

    CB-Long-Term Safety Study (CB-LTSS)

    Enrolling by invitation
    • Lymphoma, Non-Hodgkin
    • +7 more
    • Allogeneic CAR-T therapy
    • Irvine, California
    • +3 more
    Nov 18, 2022